Clinical data have validated that RIT is both more cost effective and more efficacious than nonradioactive immunotherapy. More recently, several single-arm studies have demonstrated that upfront RIT administered either alone or with chemotherapy to previously untreated indolent NHL patients produces overall response rates of 90-100 %, complete response rates of 60-95 % and durable remissions...................................
However, too much cold anti-CD20 antibody over a long time can result in blocking of the CD20 antigen on tumour cells and thus reduce the effect of anti-CD20 RIT. Both clinical and non-clinical studies have shown that in some circumstances quite low rituximab concentrations in the blood can reduce tumour cell targeting and thus impair the clinical efficacy of CD20-directed RIT. A solution to this problem might be to omit cold rituximab from the last cycles of therapy before RIT. Alternatively; one could choose to target another B-cell surface antigen such as CD37.

Link 22 Mars. 2018 . http://www.sumobrain.com/patents/wipo/Treatment-non-hodgkin-lymphoma-using/WO2018050851A1.html

13.Juni .2018 : The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Jostein Dahle......................Betalutin a new rising star in haematology


News from Rambler.ru / Published Sep 11, 2018

Clinical testing is the next stepp........ weekly injection is the best

http://www.gratisoa.org/journals/index.php/GJCT/article/view/1091




Lobster and wine in the weekend.....................